325. A Novel Utrophin-Based Genome Engineering Strategy for Duchenne Muscular Dystrophy Utilizing Recombinases and CRISPR/Cas9

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)35338-2
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Elsevier BV

Related search

CRISPR-Generated Animal Models of Duchenne Muscular Dystrophy

2020English

Genome Editing Gene Therapy for Duchenne Muscular Dystrophy

Journal of Neuromuscular Diseases
Neurology
2015English

Corrigendum: Muscle-Specific CRISPR/Cas9 Dystrophin Gene Editing Ameliorates Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2017English

Duchenne Muscular Dystrophy

Physiotherapy
Physical TherapySports TherapyRehabilitation
1990English

Exon Skipping: A First in Class Strategy for Duchenne Muscular Dystrophy

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2016English

Duchenne Muscular Dystrophy

English

Duchenne Muscular Dystrophy

Methods in Molecular Biology
GeneticsMolecular Biology
2018English

Duchenne Muscular Dystrophy

2020English

Alternative Utrophin mRNAs Contribute to Phenotypic Differences Between Dystrophin-Deficient Mice and Duchenne Muscular Dystrophy

FEBS Letters
GeneticsCell BiologyMolecular BiologyBiochemistryStructural BiologyBiophysics
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy